Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro.
Some time has passed since the torrent of discussion surrounding the cardiovascular risk of pushing up hemoglobin concentrations in dialysis patients with erythropoietin. The debate here reflects a look back on the tension produced by confusing data and outcomes. Is it the target hemoglobin per se or the high doses of erythropoietin in subsets of resistant patients that is the problem? You decide.
Singh
Ajay K
AK
Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. asingh@partners.org
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000150:complications*; D012307:Risk Factors
D006454:Hemoglobins; D004921:Erythropoietin